Pillar Biosciences, CellCarta partner on decentralized NGS tumor profiling for oncology trials

Pillar Biosciences' oncoReveal NGS panel portfolio sits at the center of a [multi-year global strategic partnership](https://www.prnewswire.com/news-releases/cellcarta-and-pillar-biosciences-announce-multi-year-global-strategic-partnership-to-expand-rapid-decentralized-tumor-profiling-for-oncology-clinical-trials-302732033.html) with CellCarta, a Montreal-based contract research laboratory. ### Deal context The collaboration pairs Pillar’s kitted NGS panels, designed for use in local laboratories, with CellCarta’s facilities across North America, Europe, Asia-Pacific, and China. The companies said the model is intended to support faster patient stratification in biomarker-driven trials by reducing reliance on centralized testing and associated sample logistics. Pillar’s oncoReveal portfolio includes panels covering solid tumors and hematologic malignancies, supported by its proprietary multiplex PCR chemistry and PiVAT bioinformatics platform. The portfolio also includes companion diagnostic claims approved by the US FDA for specific biomarkers, including EGFR mutations in non-small cell lung cancer and KRAS mutations in colorectal cancer. For CellCarta, the partnership expands its genomics capabilities within its broader biomarker services platform. The companies said the collaboration could also support future companion diagnostic development programs aligned with biopharma-sponsored clinical trials. The agreement is structured as a services and technology integration partnership and does not include drug assets or disclosed milestone or royalty terms. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/ngs-tumor-profiling-partnership-pillar)